Terms: = Breast cancer AND PIM1, PIM, 5292, ENSG00000137193, P11309
73 results:
1. pim kinase inhibitor AZD1208 in conjunction with Th1 cytokines potentiate death of breast cancer cellsin vitrowhile also maximizing suppression of tumor growthin vivo when combined with immunotherapy.
Anwar A; Lepore C; Czerniecki BJ; Koski GK; Showalter LE
Cell Immunol; 2024; 397-398():104805. PubMed ID: 38244265
[TBL] [Abstract] [Full Text] [Related]
2. Epigenomic Profiling Advises Therapeutic Potential of Leukotriene Receptor Inhibitors for a Subset of Triple-Negative breast Tumors.
Kalinkin AI; Sigin VO; Kuznetsova EB; Ignatova EO; Vinogradov II; Vinogradov MI; Vinogradov IY; Zaletaev DV; Nemtsova MV; Kutsev SI; Tanas AS; Strelnikov VV
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139172
[TBL] [Abstract] [Full Text] [Related]
3. Tailored horseshoe-shaped nicotinonitrile scaffold as dual promising c-Met and pim-1 inhibitors: Design, synthesis, SAR and in silico study.
Mohamady S; Khalil AF; Naguib BH; Nafie MS; Tawfik HO; Shaldam MA
Bioorg Chem; 2024 Feb; 143():106988. PubMed ID: 37995644
[TBL] [Abstract] [Full Text] [Related]
4. Design, synthesis, and evaluation of a mitoxantrone probe (MXP) for biological studies.
Wallin S; Singh S; Borgstahl GEO; Natarajan A
Bioorg Med Chem Lett; 2023 Oct; 94():129465. PubMed ID: 37669721
[TBL] [Abstract] [Full Text] [Related]
5. Neoprzewaquinone A Inhibits breast cancer Cell Migration and Promotes Smooth Muscle Relaxation by Targeting pim1 to Block ROCK2/STAT3 Pathway.
Zhao G; Ren Y; Yan J; Zhang T; Lu P; Lei J; Rao H; Kang X; Cao Z; Peng F; Peng C; Rao C; Li Y
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982538
[No Abstract] [Full Text] [Related]
6. Antitumor activity of the protein kinase inhibitor 1-(β-D-2'-deoxyribofuranosyl)-4,5,6,7-tetrabromo- 1H-benzimidazole in breast cancer cell lines.
Koronkiewicz M; Kazimierczuk Z; Orzeszko A
BMC Cancer; 2022 Oct; 22(1):1069. PubMed ID: 36243702
[TBL] [Abstract] [Full Text] [Related]
7. pim kinases phosphorylate lactate dehydrogenase A at serine 161 and suppress its nuclear ubiquitination.
Mung KL; Meinander A; Koskinen PJ
FEBS J; 2023 May; 290(9):2489-2502. PubMed ID: 36239424
[TBL] [Abstract] [Full Text] [Related]
8. Targeting pim2 by JP11646 results in significant antitumor effects in solid tumors.
Katsuta E; Gil-Moore M; Moore J; Yousif M; Adjei AA; Ding Y; Caserta J; Baldino CM; Lee KP; Gelman IH; Takabe K; Opyrchal M
Int J Oncol; 2022 Oct; 61(4):. PubMed ID: 35920189
[TBL] [Abstract] [Full Text] [Related]
9. pim1/STAT3 axis: a potential co-targeted therapeutic approach in triple-negative breast cancer.
Mahata S; Sahoo PK; Pal R; Sarkar S; Mistry T; Ghosh S; Nasare VD
Med Oncol; 2022 May; 39(5):74. PubMed ID: 35568774
[TBL] [Abstract] [Full Text] [Related]
10. Design, synthesis, evaluation of new 3-acetylisoxazolines and their hybrid analogous as anticancer agents: In vitro and in silico analysis.
Fawzi M; Oubella A; Bimoussa A; Bamou FZ; Khdar ZA; Auhmani A; Riahi A; Robert A; Morjani H; Itto MYA
Comput Biol Chem; 2022 Jun; 98():107666. PubMed ID: 35381466
[TBL] [Abstract] [Full Text] [Related]
11. Topical advances in pim kinases and their inhibitors: Medicinal chemistry perspectives.
Walhekar V; Bagul C; Kumar D; Muthal A; Achaiah G; Kulkarni R
Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188725. PubMed ID: 35367531
[TBL] [Abstract] [Full Text] [Related]
12. Identification of a risk prediction model for clinical prognosis in HER2 positive breast cancer patients.
Zhou D; Wu Y; Jiang K; Xu F; Hong R; Wang S
Genomics; 2021 Nov; 113(6):4088-4097. PubMed ID: 34666190
[TBL] [Abstract] [Full Text] [Related]
13. Synergistic pim kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer.
Kunder R; Velyunskiy M; Dunne SF; Cho BK; Kanojia D; Begg L; Orriols AM; Fleming-Trujillo E; Vadlamani P; Vialichka A; Bolin R; Perrino JN; Roth D; Clutter MR; Zielinski-Mozny NA; Goo YA; Cristofanilli M; Mendillo ML; Vassilopoulos A; Horiuchi D
Cell Chem Biol; 2022 Mar; 29(3):358-372.e5. PubMed ID: 34525344
[TBL] [Abstract] [Full Text] [Related]
14. The Second-Generation pim Kinase Inhibitor TP-3654 Resensitizes ABCG2-Overexpressing Multidrug-Resistant cancer Cells to Cytotoxic Anticancer Drugs.
Wu CP; Li YQ; Chi YC; Huang YH; Hung TH; Wu YS
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502348
[TBL] [Abstract] [Full Text] [Related]
15. Therapeutic targeting of pim KINASE signaling in cancer therapy: Structural and clinical prospects.
Rathi A; Kumar D; Hasan GM; Haque MM; Hassan MI
Biochim Biophys Acta Gen Subj; 2021 Nov; 1865(11):129995. PubMed ID: 34455019
[TBL] [Abstract] [Full Text] [Related]
16. Case-case analysis addressing ascertainment bias for multigene panel testing implicates BRCA1 and PALB2 in endometrial cancer.
Johnatty SE; Pesaran T; Dolinsky J; Yussuf A; LaDuca H; James PA; O'Mara TA; Spurdle AB
Hum Mutat; 2021 Oct; 42(10):1265-1278. PubMed ID: 34245638
[TBL] [Abstract] [Full Text] [Related]
17. pim kinases inhibit AMPK activation and promote tumorigenicity by phosphorylating LKB1.
Mung KL; Eccleshall WB; Santio NM; Rivero-Müller A; Koskinen PJ
Cell Commun Signal; 2021 Jun; 19(1):68. PubMed ID: 34193159
[TBL] [Abstract] [Full Text] [Related]
18. Comparison of Anticancer Activity of
Koygun G; Arslan E; Zengin G; Orlando G; Ferrante C
Biomolecules; 2021 Apr; 11(5):. PubMed ID: 33946222
[No Abstract] [Full Text] [Related]
19. pim-induced phosphorylation of Notch3 promotes breast cancer tumorigenicity in a CSL-independent fashion.
Landor SKJ; Santio NM; Eccleshall WB; Paramonov VM; Gagliani EK; Hall D; Jin SB; Dahlström KM; Salminen TA; Rivero-Müller A; Lendahl U; Kovall RA; Koskinen PJ; Sahlgren C
J Biol Chem; 2021; 296():100593. PubMed ID: 33775697
[TBL] [Abstract] [Full Text] [Related]
20. Androgen Receptor and
Ntzifa A; Strati A; Koliou GA; Zagouri F; Pectasides D; Pentheroudakis G; Christodoulou C; Gogas H; Magkou C; Petraki C; Kosmidis P; Aravantinos G; Kotoula V; Fountzilas G; Lianidou E
Cancer Genomics Proteomics; 2021; 18(2):147-156. PubMed ID: 33608311
[TBL] [Abstract] [Full Text] [Related]
[Next]
